Teva, looking to reduce debt, is exploring a sale of its specialty cancer treatments, says Bloomberg sources.
Bloomberg sources also say sale considerations are preliminary and Teva could change its mind. Revenue from the oncology division fell 5 percent to $1.14 billion last year.
The generic giant's debt continues to grow as sales are hit by competition from rival teherapies. Teva's CEO Erez Vigodman resigned in February as Teva struggled through a series of missteps and contraversies.
Read the Bloomberg story